Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains - Summary - MDSpire

Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains

  • By

  • Stefano Di Donato

  • Juan José Alegre-Sancho

  • Anastas Batalov

  • Zguro Batalov

  • Silvia Bellando-Randone

  • Carmela Coccia

  • Marco De Pinto

  • Dilia Giuggioli

  • Michael Hughes

  • May 30, 2026

  • 0 min

Share

Objective:

To report the real-world collective international experience of JAKi treatment concerning the safety and effectiveness in patients with systemic sclerosis (SSc).

Key Findings:
  • Remove speculative language and ensure all claims are directly supported by the source.
  • Consider rephrasing to focus on findings that are explicitly stated in the source.
Interpretation:

Remove this section entirely.

Limitations:
  • Retrospective nature may introduce bias.
  • Limited generalizability due to multicenter design and small sample sizes.
  • Lack of formal exclusion criteria may affect the homogeneity of the cohort.
Conclusion:

Remove this section entirely.

Original Source(s)

Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains

  • by Stefano Di Donato, Juan José Alegre-Sancho, Anastas Batalov, Zguro Batalov, Silvia Bellando-Randone, Carmela Coccia, Marco De Pinto, Dilia Giuggioli, Michael Hughes

  • May 30, 2026

Related Content

Semaglutide Use Linked to Erythromelalgia Remission

Case details diagnostic workup and rapid symptom resolution following GLP-1 receptor agonist initiation.

Alterations in B-cell Subsets and Clinical Predictors of Response to Telitacicept in Antiphospholipid Antibody-Positive SLE Patients: A Prospective Observational Study

AAO Updates HCQ Retinopathy Guidance

Updated recommendations emphasize dosing limits and screening for toxicity risk.